Ranbaxy (US) ▼
- .
- .
- .
- .
Ranbaxy Inc. is the North American commercial arm of Ranbaxy Laboratories Limited (Ranbaxy), a research based international pharmaceutical company serving customers in more than 150 countries. In 1994, Ranbaxy entered the US healthcare system with a focus on the generic pharmaceutical sector. Ranbaxy Inc.
Read More
Read More
Worldwide Presence
Update on Atorvastatin Recall in USA
On March 26, 2013, Ranbaxy Pharmaceuticals Inc., the U.S. subsidiary of Ranbaxy Laboratories Limited, resumed the supply of Atorvastatin calcium tablets that includes...Read More
Our products
Latest News
-
Ranbaxy Announces Conclusion Of Previously Disclosed Investigation By U.S. Department Of Justice
Ranbaxy Laboratories Ltd. (RLL, NSE: RANBAXY, BSE: 500359) (“Ranbaxy”), today announced that a previously disclosed investigation by the U.S. Department… -
Ranbaxy to market Desvenlafaxine Base Extended Release Tablets in The U.S.
Enters into an in-licensing business agreement with Alembic Princeton, NJ – March 05, 2013 — Ranbaxy Pharmaceuticals Inc. (RPI), a… -
Ranbaxy Issues Voluntary Nationwide Recall of 41 lots of Atorvastatin Calcium Tablets 10 mg, 20 mg and 40 mg Due to Potential Presence of Foreign Substance
Ranbaxy Inc. initiated a voluntary recall of 41 affected lots of Atorvastatin Calcium Tablets (10 mg, 20 mg and 40… -
RANBAXY LAUNCHES ABSORICA™ (ISOTRETINOIN) CAPSULES IN THE U.S. HEALTHCARE MARKET
Ranbaxy Laboratories, Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced the sales and promotion launch… -
RANBAXY LAUNCHES AUTHORIZED GENERIC OF EVOXAC IN THE U.S. HEALTHCARE MARKET
Princeton, New Jersey Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (Ranbaxy), has launched the authorized… -
RANBAXY LAUNCHES AUTHORIZED GENERIC OF PIOGLITAZONE IN THE U.S.
Princeton, New Jersey Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd. (RLL), has launched authorized generic pioglitazone… -
RANBAXY ENTERS INTO AN IN-LICENSING AGREEMENT WITH GILEAD SCIENCES TO PROMOTE ACCESS TO REDUCED COST GENERIC EMTRICITABINE AND EMTRICITABINE-CONTAINING FIXED-DOSE ANTIRETROVIRALS IN DEVELOPING COUNTRIES
Gurgaon, India Ranbaxy Laboratories Limited (Ranbaxy) announced today that it has entered into an in-licensing agreement with Gilead Sciences, Inc.… -
RANBAXY COMMENDS NEW IMS STUDY WHICH CREDITS GENERIC PRESCRIPTION DRUGS WITH $1 TRILLION SAVINGS IN U.S. HEALTHCARE COSTS OVER PAST 10 YEARS
Princeton, NJ Ranbaxy Pharmaceuticals Inc. (RPI) today acknowledged an important, new study released by the Generic Pharmaceutical Association (GPhA) which…
